
New in Diabetes Drugs: Healthier Hearts, Improved Glucose Management
New in Diabetes Drugs: Healthier Hearts, Improved Glucose Management
Research presented at ADAs 2017 conference shows exciting advances in a host of diabetes drugs including heart benefits, improved glucose control, lower cholesterol, weight loss, less hypoglycemia, and more
The recent American Diabetes Associations (ADA) 77th Scientific Sessions brought leaders in diabetes research, care, and advocacy to sunny San Diego, CA, for a week filled with learning about the latest in the field of diabetes.
The most noteworthy drug updates from the conference included:
SGLT-2 inhibitors (Jardiance, Farxiga, Invokana): Announced earlier this year, CVD-REAL was a very large real-world study that compared how well SGLT-2 inhibitors work in daily life versus other glucose-lowering drugs like metformin , DPP-4 inhibitors , GLP-1 agonists , and insulin. The results suggested that the entire category (the class) of SGLT-2 inhibitors Jardiance, Farxiga, and Invokana has a positive effect on heart health. This follows positive results from large trials for Jardiance ( EMPA-REG OUTCOME ) and Invokana ( CANVAS ) that also demonstrated a heart benefit. A more rigorous heart outcomes trial for Farxiga is ongoing (DECLARE). The CVD-REAL study did not collect amputation or other safety data, so its not clear if the amputation concerns observed for Invokana might apply to the other drugs in the SGLT-2 inhibitor class too. See a separate diaTribe article on the CANVAS results presented at ADA 2017 here .
Xultophy: The DUAL VII trial compared Xultophy, a combination drug of Tresiba (a basa
Continue
reading